Abstract
Purpose
Methods
Findings
Implications
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
- Pathogenesis and current approaches to control of varicella-zoster virus infections.Clin Microbiol Rev. 2013; 26: 728-743
- Recent advances in varicella-zoster virus infection.Ann Intern Med. 1999; 130: 922-932
- Zoster in patients infected with HIV: a review.Am J Med Sci. 2001; 321: 372-380
- Post-herpetic neuralgia in older patients. Incidence and optimal treatment.Drugs Aging. 1994; 5: 411-418
- Images in clinical medicine. Left sixth cranial nerve palsy with herpes zoster ophthalmicus.N Engl J Med. 2005; 353: e14
- Ogilvie syndrome and herpes zoster: case report and review of the literature.J Emerg Med. 2010; 39: 696-700
- Association of an attack of varicella and an achalasia.J Emerg Med. 1995; 90: 1188-1189
- Live attenuated varicella vaccine for prevention of herpes zoster.Biologicals. 1997; 25: 227-230
- The protean neurologic manifestations of varicella-zoster virus infection.Clev Clin J Med. 2007; 74 (496, 498-499): 489-494
- Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.J Med Econ. 2010; 13: 537-551
- Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?.Am J Epidemiol. 2011; 174: 1054-1061
- The epidemiology of varicella-zoster virus infections.Infect Dis Clin N Am. 1996; 10: 571-581
- The incidence of herpes zoster.Arch Intern Med. 1995; 155: 1605-1609
- A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.N Engl J Med. 2005; 352: 2271-2284
- Herpes zoster vaccine (Zostavax).Med Lett Drugs Ther. 2006; 48: 73-74
- Live vaccine used to prevent the spread of varicella in children in hospital.Lancet. 1974; 2: 1288-1290
- Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.Ann Intern Med. 2010; 152: 545-554
- Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence sub-study.Clin Infect Dis. 2012; 55: 1320-1328
- Long-term persistence of zoster vaccine efficacy.Clin Infect Dis. 2015; 60: 900-909
- Vaccination against herpes zoster and postherpetic neuralgia.J Infect Dis. 2008; 197: S228-S236
- Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.Clin Infect Dis. 2012; 54: 922-928
- Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults.J Am Geriatr Soc. 2010; 58: 1634-1641
Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed., second printing. 2012. Washington DC: Public Health Foundation. www.cdc.gov/vaccines/pubs/pinkbook. Accessed January 23, 2015
- Zostavax [package insert].Merck and Co., Inc, Whitehouse Station, NJ2014
- Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?.Vaccine. 2012; 30: 2795-2800
- Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Clin Infect Dis. 2007; 44: 1280-1288
- Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.Vaccine. 2008; 27: 1454-1467
- The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.Hum Vaccines. 2008; 4: 238-245
- Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Vaccine. 2007; 25: 8326-8337
- A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity.Med Care. 1996; 34: 220-233
Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint [press release]. London, UK: GlaxoSmithKline plc; 2014. http://www.gsk.com/en-gb/media/press-releases/2014/pivotal-phase-iii-study-of-gsk-shingles-candidate-vaccine-meets-its-primary-endpoint/ Accessed 2015.